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Abstract
Infants and children under five years of age are the most vulnerable to malaria with over 1,700
deaths per day from malaria in this group. However, until recently, there were no WHO-endorsed
paediatric anti-malarial formulations available.
Artemisinin-based combination therapy is the current standard of care for patients with
uncomplicated falciparum malaria in Africa. Artemether/lumefantrine (AL) meets WHO pre-
qualification criteria for efficacy, safety and quality. Coartem®, a fixed dose combination of
artemether and lumefantrine, has consistently achieved cure rates of >95% in clinical trials.
However, AL tablets are inconvenient for caregivers to administer as they need to be crushed and
mixed with water or food for infants and young children. Further, in common with other anti-
malarials, they have a bitter taste, which may result in children spitting the medicine out and not
receiving the full therapeutic dose.There was a clear unmet medical need for a formulation of AL
specifically designed for children.
Ahead of a call from WHO for child-friendly medicines, Novartis, working in partnership with
Medicines for Malaria Venture (MMV), started the development of a new formulation of AL for
infants and young children: Coartem® Dispersible. The excellent efficacy, safety and tolerability
already demonstrated by AL tablets were confirmed with dispersible AL in a large trial comparing
the crushed tablets with dispersible tablets in 899 African children with falciparum malaria. In the
evaluable population, 28-day PCR-corrected cure rates of >96% were achieved. Further, its sweet
taste means that it is palatable for children, and the dispersible formulation makes it easier for
caregivers to administer than bitter crushed tablets. Easing administration may foster compliance,
hence improving therapeutic outcomes in infants and young children and helping to preserve the
efficacy of ACT.
Open AccessBackground
Launched on 6 December 2007, ‘Make medicines child size’
is a five-year global campaign spearheaded by the World
Health Organization (WHO) [1]. The aim is to raise
awareness and accelerate action to address the need for
improved availability and access to safe and effective
child-specific medicines for all children under the age of
15. To achieve this goal, more research is needed, more
medicines need to be developed, and improved access
measures are essential. At present, many medicines are
not developed specifically for children or with the specific
needs of children taken into account, and are often not
available in suitable dosage forms.
The  ‘Make medicines child size’ campaign is aiming to
change that reality. Both EU and US legislation encourage
the development of paediatric formulations and there is
now a shift from protecting children from clinical trials to
protecting them through clinical trials. As children tend to
metabolize medicines differently to adults, they need to
be given a tailored dosage in a suitable, stable format that
is palatable and easy to administer. Small children have
difficulty swallowing whole tablets, but other formula-
tions, such as dispersible tablets or syrups, are much easier
to take.
According to WHO, over nine million children under five
years old die each year, with over 1,700 malaria-related
deaths every day in this group [2]. Access to prompt and
effective treatment of malaria is the main challenge in
Africa, although dose accuracy and adherence to the treat-
ment schedule are equally important to ensure an ade-
quate therapeutic response [3].
Despite the fact that infants and children bear the greatest
burden of malaria, there has been, until recently, no anti-
malarial agent specifically formulated for this vulnerable
group. Research into the development of alternative
formulations for children has been limited, and although
specific paediatric formulations such as syrups and sus-
pensions exist (e.g. artemether/lumefantrine suspension
[4]), these still may involve reconstitution or volume
measurement in the field. Therefore, there is still a need
for a formulation that facilitates easy and accurate dosing.
Addressing an unmet need
To date, artemisinin derivatives are the only class of anti-
malarial agents to which parasite resistance has not been
reported in Africa. WHO guidelines specifically recom-
mend the use of artemisinin-based combination therapy
(ACT) for the treatment of uncomplicated falciparum
malaria [5]. Artemether/lumefantrine (AL) is an ACT that
meets WHO prequalification criteria for efficacy, safety
and quality [6] and AL (Coartem®) has been recently
approved by the USA FDA [7].
Coartem®, a fixed dose combination of artemether and
lumefantrine, has consistently achieved cure rates of
>95% in clinical trials of children with malaria and was
shown to be safe and well tolerated [8,9].
AL tablets are available in paediatric doses; however, they
must be crushed for infants and small children as whole
tablets may present a choking hazard. The crushed tablets,
in common with many anti-malarials, have a bitter taste
that may cause children to spit them out, and may result
in a sub-therapeutic dose being taken. Further, crushing of
the tablets by caregivers at home may result in loss of
active ingredients and thus under dosing. Together, these
factors could result in an opportunity for parasite
resistance to develop.
A public-private partnership
Recognizing that few medicines have been successfully
created to address the needs of children with malaria,
Novartis and Medicines for Malaria Venture (MMV)
formed a public-private partnership with the aim of
developing a paediatric formulation of AL. MMV is a
global, non-profit organization created to discover,
develop and deliver safe, effective and affordable anti-
malarials for vulnerable populations, whilst Novartis is a
global pharmaceutical company with a wealth of
experience in drug development and a team of investi-
gators in endemic countries. Pooling their resources
meant that the partners were ideally placed to develop a
formulation of AL specifically designed for infants and
young children.
Challenges in developing a paediatric formulation
The biggest challenge in developing a new formulation is
to ensure that it is acceptable to all stakeholders. For
patients, it must be palatable and easy to take. For
caregivers, accessibility and ease of administration to a
sick child is a prime concern. For regulatory authorities,
there must be sufficient data to support the use of the new
formulation in the target population in terms of quality,
efficacy and safety. Purchasers are most concerned about
cost and availability.
The choice of which paediatric formulation to develop was
carefully considered. Both syrups and powder for recon-
stitution, which are used for existing paediatric drug formu-
lations, have several disadvantages: they are bulky to supply
and store, and once opened/reconstituted, the stability and
hygiene of the formulations can no longer be guaranteed.
Accurate dosing of syrups and powder for reconstitution,
typically delivered in a multi-dose format, may be difficult
as it requires accurate volume measurement in the field.
The development of a dispersible tablet of AL allowed an
accurate dose of the active ingredient to be contained in a
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existing AL tablets. The dispersible tablets are simpler for
caregivers to prepare and administer than crushed bitter
tablets and easier for sick children and infants to take
[10]. They require only a small amount of water for dis-
persion [10]. The availability of clean, safe water for
dispersion of the tablet is not considered to be an issue, as
water is needed to facilitate swallowing of any tablet,
whether a crushed AL tablet or another medication.
Finally, the existing colour-coded packaging with clear
step-by-step instructions for use could easily be adapted
for the packaging of a dispersible AL formulation, build-
ing on the education and understanding that has already
been achieved.
Palatability
Palatability is a contributing factor to compliance in
children’s medicines [11]. The success of dispersible AL in
terms of acceptability to children was dependent on a
flavour that masks the bitter taste.
A randomized, single-centre cross-over study (Study
COA566B2101, Novartis Pharma AG. Reference Investi-
gators - Abdulla et al. Personal Communication) was
carried out with healthy African schoolchildren to
evaluate the palatability of three flavours of AL for oral
suspension. Strawberry, orange and cherry flavours were
tested, and overall, cherry was found to be the preferred
flavour. Even though this fruit is not native to Africa it is
often found in soft drinks and other medications such as
antibiotic syrups.
Dispersible artemether/lumefantrine
development programme
Once a paediatric formulation of AL had been developed
it was subjected to a rigorous clinical development
programme consisting of several key steps: testing the
formulation for stability in hot and humid conditions,
comparing the bioavailability with current marketed AL
tablets in children with malaria, and demonstrating clinical
non-inferiority (efficacy and safety) to the marketed AL
tablets in children with malaria. The culmination of the
programme was filing for approval with Swissmedic (ICH
stringent regulatory authority) and launch across Africa
following registration in endemic countries.
Bioavailability of dispersible
artemether/lumefantrine
Before embarking on a large efficacy and safety clinical
study in children, the pharmacokinetic (PK) performance
of the dispersible tablet was investigated and compared to
regular AL tablets. The study objective was to assess bio-
availability of artemether, dihydroartemisinin (DHA, the
active metabolite of artemether) and lumefantrine (Study
COA566B2104, Novartis Pharma AG. Reference
Investigators - Abdulla et al. Personal Communication).
In this randomized, open-label, single-dose crossover
study, 48 healthy European adult volunteers with a mean
age of 33.1±7.8 years (range 22-50 years) were recruited.
Single doses of dispersible AL tablets or crushed regular
AL tablets were administered after a FDA standard break-
fast, with 4-week washout periods. Rich plasma sampling
was performed for comprehensive PK evaluation of
artemether, DHA and lumefantrine. Similar PK profiles
were found with crushed and dispersible tablets in
healthy adults for all three test compounds.
A PK comparison in children with malaria was under-
taken as part of a randomized, multicentre, investigator-
blinded study in African children [12]. Similar PK profiles
were reported for artemether, DHA and lumefantrine in
the dispersible and the crushed tablet formulations.
Efficacy of dispersible artemether/lumefantrine
AL tablets have achieved cure rates of >95% in children
with falciparum malaria [8,9]. The efficacy of the new
dispersible AL tablets was compared with that of crushed
AL tablets in a study of 899 African children with un-
complicated falciparum malaria [12]. In summary, this
was a randomized, multi-centre, two-arm, investigator
blinded trial in five African countries (Benin, Mali, Kenya,
Mozambique and Tanzania/Zanzibar).
In the evaluable population, the 28-day PCR-corrected
cure rate was 98.5% for the group receiving crushed AL
tablets and 97.8% for the group receiving dispersible AL
tablets [12]. The PCR-adjusted cure rates for the two
groups were also comparable at day 14 and day 42 [12].
Notably, the cure rates were similar across three different
body weight categories/dosing regimen groups (Figure 1)
[12]. In addition, there were no significant differences
between those receiving crushed tablets and those
receiving dispersible tablets with regard to median time to
parasite clearance and median time to fever clearance
(Figures 2 and 3) [12].
Only a small proportion of patients had gametocytes after
day 8 (crushed tablet 1.2%, dispersible tablet 0.5%) [12].
Gametocyte clearance could not be assessed as too few
patients had gametocytes at baseline. However, the low
prevalence of gametocytes post-treatment with AL
observed in this large study population suggests that this
treatment results in low gametocyte carriage and so may
reduce malaria transmission in highly endemic areas.
Safety
AL tablets have demonstrated an excellent safety profile in
children with falciparum malaria [8,9]. The safety and
tolerability of dispersible AL tablets was examined in the
same randomized study of 899 African children
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and incidence of adverse events as crushed AL tablets [12].
Tolerability was good with both crushed and dispersible
tablets, with no difference in the pattern and overall
incidence of adverse events (AEs) across both formula-
tions. No new or unexpected AEs were seen in either treat-
ment group. Most commonly reported AEs were related to
malaria (e.g. pyrexia), with only 12.4% (56) and 9.4%
(42) of patients with an AE suspected to be related to the
crushed tablets or the dispersible tablets respectively. The
most frequent drug-related AE was vomiting, but only a
fraction of patients needed rescue medication due to
vomiting of study medication (2.4% in the crushed tablet
group; 1.3% in the dispersible tablet group). Vomiting
was more frequently reported in the lowest body weight
category. Other drug-related AEs occurred in less than
0.9% of patients in either group, and no clinically rele-
vant changes in vital signs or laboratory evaluations were
observed.
There were three deaths during the study. In the group
taking dispersible tablets, one patient died of haemor-
rhage following scarification by a traditional healer, and
one from an unspecified infection accompanied by severe
dehydration. One patient in the crushed tablet group died
of severe P. falciparum malaria (new infection).
Dispersible artemether/lumefantrine packaging
Packaging for dispersible AL was created to further build
on the legacy of the packaging that already exists for AL
tablets. The packaging was designed based on indepen-
dent field testing with rural African health workers,
patients and community members, including mothers. As
literacy levels vary, the packaging was made as graphical
as possible (Figure 4). There are clear, three-step instruc-
tions on how to make up the dispersible AL and give the
dispersed tablet(s) to the child (Figure 5). Key features of
the packaging are diagrams that facilitate understanding
of the dosing regimen and the need to complete the full
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Figure 1
Similar efficacy across body weight groups with crushed AL
tablet and dispersible AL tablet (PCR-corrected cure rate in
the modified intent-to-treat population). Adapted from
Abdulla et al [12].
Figure 2
Similar median time to parasite clearance with crushed AL
tablets and dispersible AL tablets (among patients with fever
at baseline). Adapted from Abdulla et al [12].
Figure 3
Similar median time to fever clearance is with crushed AL
tablets and dispersible AL tablets. Adapted from Abdulla et
al [12].three-day course. For example, the rationale for com-
pliance with the three-day course of tablets is shown
visually by the number of parasites decreasing as the
course of medicine is completed. It clearly shows that
patients must complete the full course to be cured.
The packaging serves as an educational tool that the health
worker can use to teach the caregiver how and when to
administer the dispersible AL and serves as a visual aid for
the caregiver once at home. Ultimately, the packaging
supports best practice in both local health service
provision and patient use of dispersible AL. Further, it is
easy to store and hygienic, with each dispersible tablet
enclosed in a separate foil blister.
Administration of dispersible
artemether/lumefantrine and approval status
Dispersible AL tablets rapidly disperse (<1 min) in water
to form a sweet-tasting medicine [10]. They require only a
small amount of water to disperse in a spoon or a beaker
and have no need for any special equipment [10]. They
can be administered with food or milk [10]. Dispersible
tablets are simpler for caregivers to prepare and adminis-
ter than bitter crushed tablets [10] and will hopefully
prove easier for infants and children to take.
Dispersible AL was approved by Swissmedic in December
2008 and received WHO prequalification in February
2009. It has been approved in 24 African countries to date.
Conclusion
Dispersible tablets are expected to contribute to ease of
administration of anti-malarial medication in those most
vulnerable to malaria, i.e. infants and children. Further
studies will be needed to establish the impact of the
dispersible tablets on compliance, but it is hoped that the
simplicity of administration will contribute greatly to
adherence to the full three-day course of tablets,
improving malaria morbidity and mortality in infants
and young children and minimizing the opportunity for
emergence of resistance. Novartis and MMV continue to
work together to ensure the rapid delivery and adoption
of dispersible AL to achieve optimal and affordable treat-
ment of malaria that is tailored to the needs of children
and their caregivers. Other partners such as African
governments are striving to make sure that the dispersible
tablets are reaching those people who need it the most, as
well as organising training courses for healthcare workers
to facilitate the switch from regular AL tablets to the
dispersible formulation. This transition to the new
formulation is not thought to present any significant
challenges as the dosing pattern is the same as regular AL
tablets. Procurement is underway; the dispersible tablets
have already been delivered to countries such as Zambia
and Mali, with more countries to follow imminently.
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Figure 4
Coartem® Dispersible packaging.
Figure 5
Step-by-step instructions on how to make up the dispersible
AL tablets for easy administration to children.The tablet
disperses in a small amount of water to produce a sweet-
tasting solution.This article is part of Malaria Journal Volume 8 Supplement 1: Coartem®:
reviewing the impact on the malaria landscape.  The full contents of the
supplement are available online at http://www.malariajournal.com/
supplements/8/S1. Publication of the supplement has been sponsored by
Novartis Pharma AG.
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